Intra-Cellular Therapies Inc (ITCI, Financial) is set to release its Q3 2024 earnings on Oct 30, 2024. The consensus estimate for Q3 2024 revenue is $172.35 million, and the earnings are expected to come in at -$0.20 per share. The full year 2024's revenue is expected to be $666.57 million and the earnings are expected to be -$0.69 per share. More detailed estimate data can be found on the Forecast page.
Intra-Cellular Therapies Inc (ITCI, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Intra-Cellular Therapies Inc (ITCI) for the full year 2024 have increased from $663.23 million to $666.57 million. For 2025, the revenue estimates have declined from $931.91 million to $919.36 million. Earnings estimates for the full year 2024 have declined from -$0.57 per share to -$0.69 per share, and for 2025, the earnings estimates have decreased from $1.26 per share to $0.69 per share.
Intra-Cellular Therapies Inc (ITCI, Financial) Reported History
In the previous quarter of June 30, 2024, Intra-Cellular Therapies Inc's (ITCI) actual revenue was $161.39 million, which beat analysts' revenue expectations of $157.88 million by 2.22%. Intra-Cellular Therapies Inc's (ITCI) actual earnings were -$0.16 per share, which beat analysts' earnings expectations of -$0.202 per share by 20.79%. After releasing the results, Intra-Cellular Therapies Inc (ITCI) was down by -5.81% in one day.
Intra-Cellular Therapies Inc (ITCI, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 15 analysts, the average target price for Intra-Cellular Therapies Inc (ITCI) is $96.17 with a high estimate of $130 and a low estimate of $74. The average target implies an upside of 25.19% from the current price of $76.82.
Based on GuruFocus estimates, the estimated GF Value for Intra-Cellular Therapies Inc (ITCI, Financial) in one year is $199.98, suggesting an upside of 160.32% from the current price of $76.82.
Based on the consensus recommendation from 17 brokerage firms, Intra-Cellular Therapies Inc's (ITCI, Financial) average brokerage recommendation is currently 1.9, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
